Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings

SAN DIEGO – September 30, 2016 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced clinical and preclinical data involving Toca 511 & Toca FC for the treatment of recurrent high grade glioma will be presented at the 10th International Oncolytic Virus Meeting, to be held Oct. 1-4 in Vancouver, Canada and the European Society of Gene & Cell Therapy Annual Meeting, to be held Oct. 12-21 in Florence, Italy.

Details of the International Oncolytic Virus Meeting presentation are as follows:

Presentation Type: Presentation
Title: Molecular analyses and immune activity of Toca 511 a retroviral replicating vector in preclinical models and three ascending dose trials in patients with recurrent high-grade glioma
Date and Time: Tuesday, Oct. 4, afternoon session. PT
Presenter: Douglas J. Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen

Details of the European Society of Gene & Cell Therapy presentations are as follows:

Presentation Type: Presentation
Title: Clinical update, molecular analyses, and proposed mechanism of action of Toca 511 a retroviral replicating vector in three ascending dose trials in patients with recurrent high-grade glioma
Date and Time: Friday, Oct. 21, 9:00 a.m. CET
Presenter: Douglas J. Jolly, Ph.D. executive vice president, research and pharmaceutical development at Tocagen

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. Tocagen has initiated a clinical trial of Toca 511 & Toca FC in metastatic cancers, including colorectal, pancreatic, lung, breast, renal and melanoma. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration for Toca 511 & Toca FC as a treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma multiforme (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.